Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Clinuvel Pharmaceuticals Ltd -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (7)	2/28/2005 8:29:35 PM
From: caly	Read Replies (1) \| Respond to of 52

Tuesday 1 March 2005 PMLE trial of Melanotan ® to start in Finland EpiTan Limited (ASX: EPT, ADR: EPTNY, XETRA: UR9) today announced both regulatory and ethics approval have been granted for a second PMLE trial of Melanotan in Europe (for details see Appendix 1). The trial is scheduled to start at the Turku University Central Hospital, Finland. Christer Jansén who is Professor of Dermatology and Department Chairman at University of Turku is the Principal Investigator. Professor Jansén has a wealth of dermatological experience with 40 years clinical research experience and a founding member of the Scandinavian Photo-dermatology Research Group. PMLE or “sunburn poisoning” is a UV induced skin allergy most prevalent in northern latitudes. Statistics reveal that between 10-20% of US and UK populations suffer from PMLE. PMLE usually appears as small red, burning or itchy eruptions on sun-exposed skin. It is the second most common sun-related skin problem after sunburn as seen by doctors and is most common during the spring and summer months when the level of exposure to UV radiation increases. This is the second PMLE trial involving Melanotan in Europe. The first began in Düsseldorf in January. The trials have been scheduled for the European winter/spring when people’s natural melanin levels are at their lowest. The trials are designed to test whether the melanin-inducing drug Melanotan alleviates the clinical symptoms of PMLE. The full results of the trial are expected in August.